- Home
- VALN vs ATAI Comparison
VALN vs ATAI Comparison
Compare VALN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- ATAI
- Stock Information
- Founded
- VALN 2012
- ATAI 2018
- Country
- VALN France
- ATAI Germany
- Employees
- VALN N/A
- ATAI N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- VALN Health Care
- ATAI Health Care
- Exchange
- VALN Nasdaq
- ATAI Nasdaq
- Market Cap
- VALN 542.5M
- ATAI 444.7M
- IPO Year
- VALN 2021
- ATAI 2021
- Fundamental
- Price
- VALN $6.00
- ATAI $2.61
- Analyst Decision
- VALN Strong Buy
- ATAI Strong Buy
- Analyst Count
- VALN 3
- ATAI 2
- Target Price
- VALN $15.33
- ATAI $11.00
- AVG Volume (30 Days)
- VALN 14.6K
- ATAI 5.9M
- Earning Date
- VALN 08-12-2025
- ATAI 08-12-2025
- Dividend Yield
- VALN N/A
- ATAI N/A
- EPS Growth
- VALN N/A
- ATAI N/A
- EPS
- VALN N/A
- ATAI N/A
- Revenue
- VALN $201,099,222.00
- ATAI $1,863,000.00
- Revenue This Year
- VALN $18.74
- ATAI $554.22
- Revenue Next Year
- VALN $29.26
- ATAI N/A
- P/E Ratio
- VALN N/A
- ATAI N/A
- Revenue Growth
- VALN 21.64
- ATAI 572.56
- 52 Week Low
- VALN $3.62
- ATAI $1.03
- 52 Week High
- VALN $8.66
- ATAI $2.99
- Technical
- Relative Strength Index (RSI)
- VALN 52.41
- ATAI 58.55
- Support Level
- VALN $5.57
- ATAI $2.62
- Resistance Level
- VALN $6.19
- ATAI $2.99
- Average True Range (ATR)
- VALN 0.29
- ATAI 0.23
- MACD
- VALN 0.05
- ATAI 0.02
- Stochastic Oscillator
- VALN 65.60
- ATAI 58.89
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.